A Study of Enasidenib in People With T-Cell Lymphoma

NCT06756308 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

T-cell Lymphoma

Interventions

DRUG: Enasidenib
DRUG: Rituximab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]